SAN DIEGO--(BUSINESS WIRE)--April 19, 2006--Aethlon Medical, Inc. (OTCBB:AEMD - News), a pioneer in developing therapeutic devices for infectious disease, announced today that a safety study of patients treated with the Aethlon Hemopurifier(TM) has been successfully completed at the Apollo Hospital in Delhi, India. Aethlon will include data from the study in Pandemic Influenza and Class “A” Biological Weapon regulatory filings to be submitted to the Food and Drug Administration (FDA). The demonstration of safety represents the sole human challenge for therapeutic candidates seeking clearance to treat these indications in the United States. Dr. Vijay Kher, the principal investigator of the safety study, now plans to initiate human efficacy studies of the Hemopurifier(TM) as a treatment for chronic and acute viral conditions in India. Aethlon management is currently working with Dr. Kher, advisors at Qualtran, LLC, and government officials in India to determine the infectious disease target of the initial efficacy study.
